TR201905233T4 - Dirençli bakteriyel enfeksiyonların tedavisine yönelik kombinasyon tedavisi. - Google Patents

Dirençli bakteriyel enfeksiyonların tedavisine yönelik kombinasyon tedavisi. Download PDF

Info

Publication number
TR201905233T4
TR201905233T4 TR2019/05233T TR201905233T TR201905233T4 TR 201905233 T4 TR201905233 T4 TR 201905233T4 TR 2019/05233 T TR2019/05233 T TR 2019/05233T TR 201905233 T TR201905233 T TR 201905233T TR 201905233 T4 TR201905233 T4 TR 201905233T4
Authority
TR
Turkey
Prior art keywords
pharmaceutically acceptable
acceptable salt
sulbactam
compound
imipenem
Prior art date
Application number
TR2019/05233T
Other languages
English (en)
Turkish (tr)
Inventor
Lodewijk Maria DEJONGE Boudewijn
Francois DURAND-REVILLE Thomas
Cunera Verheijen Jeroen
Tommasi Ruben
Mueller John
Original Assignee
Entasis Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entasis Therapeutics Ltd filed Critical Entasis Therapeutics Ltd
Publication of TR201905233T4 publication Critical patent/TR201905233T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TR2019/05233T 2014-11-17 2015-11-17 Dirençli bakteriyel enfeksiyonların tedavisine yönelik kombinasyon tedavisi. TR201905233T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462080667P 2014-11-17 2014-11-17

Publications (1)

Publication Number Publication Date
TR201905233T4 true TR201905233T4 (tr) 2019-05-21

Family

ID=54704148

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/05233T TR201905233T4 (tr) 2014-11-17 2015-11-17 Dirençli bakteriyel enfeksiyonların tedavisine yönelik kombinasyon tedavisi.

Country Status (31)

Country Link
US (2) US9968593B2 (enExample)
EP (1) EP3221313B1 (enExample)
JP (1) JP6764862B2 (enExample)
KR (1) KR102542392B1 (enExample)
CN (1) CN107108624B (enExample)
AU (1) AU2015350128B2 (enExample)
BR (1) BR112017010132B1 (enExample)
CA (1) CA2966632C (enExample)
CY (1) CY1121384T1 (enExample)
DK (1) DK3221313T3 (enExample)
EA (1) EA033829B1 (enExample)
ES (1) ES2717776T3 (enExample)
HK (1) HK1244798B (enExample)
HR (1) HRP20190580T1 (enExample)
HU (1) HUE044061T2 (enExample)
IL (1) IL251979B (enExample)
LT (1) LT3221313T (enExample)
ME (1) ME03357B (enExample)
MX (1) MX2017006383A (enExample)
MY (1) MY196240A (enExample)
PH (1) PH12017500852B1 (enExample)
PL (1) PL3221313T3 (enExample)
PT (1) PT3221313T (enExample)
RS (1) RS58429B1 (enExample)
SG (1) SG11201703633TA (enExample)
SI (1) SI3221313T1 (enExample)
SM (1) SMT201900187T1 (enExample)
TR (1) TR201905233T4 (enExample)
TW (1) TWI690317B (enExample)
WO (1) WO2016081452A1 (enExample)
ZA (1) ZA201703245B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017010132B1 (pt) 2014-11-17 2023-02-14 Entasis Therapeutics Limited Combinações e seus usos no tratamento de infecções bacterianas resistentes
WO2017203266A1 (en) * 2016-05-25 2017-11-30 Entasis Therapeutics Limited Combination therapy for treatment of resistant bacterial infections
CA3036557A1 (en) * 2016-09-16 2018-03-22 Entasis Therapeutics Limited Beta-lactamase inhibitor compounds
EP3301094A1 (en) * 2016-09-30 2018-04-04 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
EA037916B1 (ru) * 2017-02-08 2021-06-07 Энтасис Терапеутикс Лимитед Соединения-ингибиторы бета-лактамаз
PL3630111T3 (pl) 2017-05-08 2022-05-23 Entasis Therapeutics, Inc. Związki i sposoby leczenia zakażeń bakteryjnych
CN109422765B (zh) * 2017-09-05 2020-08-28 香港理工大学深圳研究院 C类β-内酰胺酶抑制剂及其制备方法和应用
RS64455B1 (sr) * 2018-03-13 2023-09-29 Sepsia Therapeutics S L Peptidi koji vezuju bakterije, za lečenje infektivnih bolesti i povezanih inflamatornih procesa
CN110269857A (zh) * 2018-03-14 2019-09-24 正大天晴药业集团股份有限公司 含阿维巴坦的抗菌组合物及其用途
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
KR102790878B1 (ko) 2018-08-09 2025-04-02 앤타바이오 에스에이에스 세린 베타-락타마제의 억제제로서 다이아자바이사이클로옥타논
CN111658642A (zh) * 2019-03-05 2020-09-15 广州新创忆药物临床研究有限公司 一种治疗耐碳青霉烯类抗生素鲍曼不动杆菌感染的组合物
TWI715397B (zh) * 2019-12-31 2021-01-01 高雄榮民總醫院 根據領先標準將同儕數據繪製為圖表的方法、電腦程式產品及電腦可讀取媒體
CA3176961A1 (en) * 2020-04-02 2021-10-07 Glaxosmithkline Intellectual Property Development Limited Regimen for treating a neisseria gonorrhoeae infection with gepotidacin
EP4281042A1 (en) * 2021-01-20 2023-11-29 Entasis Therapeutics Limited Fixed dosage antibiotic compositions
WO2023206580A1 (en) * 2022-04-29 2023-11-02 Entasis Therapeutics Limited Durlobactam crystalline forms
WO2025239896A1 (en) * 2024-05-16 2025-11-20 Entasis Therapeutics, Inc. Treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible isolates of acinetobacter baumannii-calcoaceticus complex

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ274915A (en) 1993-12-29 1997-11-24 Pfizer N-(hetero)aryl methyl diazabicycloalkane derivatives
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) * 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2848210B1 (fr) * 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2914923B1 (fr) 2007-04-12 2013-06-14 Novexel Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens.
MY162532A (en) * 2008-01-18 2017-06-15 Merck Sharp & Dohme Beta-lactamase inhibitors
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
EP3260551A1 (en) 2008-06-19 2017-12-27 Astra Zeneca Holding France Use of (1r,2s,5r) 1,6-diazabicyclo [3.2.1] octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2936951B1 (fr) * 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2937034B1 (fr) 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
MX338610B (es) 2011-07-26 2016-04-25 Wockhardt Ltd Composiciones farmaceuticas que comprenden sulbactam e inhibidor de beta-lactamasa.
MX362683B (es) 2011-07-26 2019-01-31 Wockhardt Ltd Composiciones farmacéuticas que comprenden antibiótico de beta-lactama, sulbactama e inhibidor de beta-lactamasa.
KR101512738B1 (ko) 2011-08-27 2015-04-17 욱크하르트 리미티드 1,6-디아자-비시클로[3,2,1]옥탄-7-온 유도체 및 세균 감염 치료에서의 그 유도체의 용도
KR101618424B1 (ko) 2011-08-30 2016-05-04 욱크하르트 리미티드 1,6-디아자비시클로[3,2,1]옥탄-7-온 유도체 및 세균 감염 치료에서의 그 유도체의 용도
BR112014003476A2 (pt) 2011-09-13 2017-03-01 Wockhardt Ltd compostos contendo nitrogênio e seu uso
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
EP2814483A2 (en) * 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
KR20140144254A (ko) 2012-03-30 2014-12-18 큐비스트 파마슈티컬즈 인코포레이티드 1,3,4-옥사디아졸 및 1,3,4-티아디아졸 β-락타마제 억제제
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
MX2014011825A (es) 2012-03-30 2015-02-20 Cubist Pharm Inc INHIBIDORES DE ISOXAZOL ß-LACTAMASA.
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
AR091222A1 (es) 2012-05-30 2015-01-21 Meiji Seika Pharma Co Ltd INHIBIDOR DE b-LACTAMASA Y PROCESO PARA PREPARARLO
CA2881169C (en) 2012-08-25 2020-06-16 Wockhardt Limited 1,6-diazabicyclo [3,2,1]octan - 7 - one derivatives and their use in the treatment of bacterial infections
CA2889793C (en) * 2012-09-03 2017-09-26 Wockhardt Limited Antibacterial compositions
CN104994860A (zh) * 2013-02-06 2015-10-21 阿斯利康(瑞典)有限公司 用于治疗医院性肺炎的组合疗法
WO2014141132A1 (en) * 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
BR112017010132B1 (pt) 2014-11-17 2023-02-14 Entasis Therapeutics Limited Combinações e seus usos no tratamento de infecções bacterianas resistentes

Also Published As

Publication number Publication date
JP6764862B2 (ja) 2020-10-07
LT3221313T (lt) 2019-03-25
BR112017010132A2 (pt) 2018-01-02
SG11201703633TA (en) 2017-06-29
AU2015350128B2 (en) 2019-05-16
PL3221313T3 (pl) 2019-07-31
EP3221313A1 (en) 2017-09-27
EA033829B1 (ru) 2019-11-29
IL251979A0 (en) 2017-06-29
HRP20190580T1 (hr) 2019-05-17
BR112017010132B1 (pt) 2023-02-14
EA201791069A1 (ru) 2017-11-30
WO2016081452A1 (en) 2016-05-26
US10376499B2 (en) 2019-08-13
ES2717776T3 (es) 2019-06-25
ME03357B (me) 2019-10-20
CY1121384T1 (el) 2020-05-29
SI3221313T1 (sl) 2019-04-30
HK1244798B (en) 2020-02-21
PH12017500852B1 (en) 2023-03-08
TW201625234A (zh) 2016-07-16
RS58429B1 (sr) 2019-04-30
CA2966632C (en) 2023-10-03
US20180289681A1 (en) 2018-10-11
CA2966632A1 (en) 2016-05-26
NZ731601A (en) 2024-02-23
MY196240A (en) 2023-03-24
AU2015350128A1 (en) 2017-06-01
CN107108624A (zh) 2017-08-29
US20180000800A1 (en) 2018-01-04
ZA201703245B (en) 2019-08-28
EP3221313B1 (en) 2019-01-09
HUE044061T2 (hu) 2019-09-30
MX2017006383A (es) 2017-08-21
KR20170082635A (ko) 2017-07-14
DK3221313T3 (en) 2019-04-08
JP2017533945A (ja) 2017-11-16
PH12017500852A1 (en) 2017-11-06
US9968593B2 (en) 2018-05-15
PT3221313T (pt) 2019-04-15
IL251979B (en) 2020-10-29
SMT201900187T1 (it) 2019-05-10
TWI690317B (zh) 2020-04-11
KR102542392B1 (ko) 2023-06-09
CN107108624B (zh) 2020-01-07

Similar Documents

Publication Publication Date Title
US10376499B2 (en) Combination therapy for treatment of resistant bacterial infections
HK1244798A1 (en) Combination therapy for treatment of resistant bacterial infections
RU2560846C1 (ru) Фармацевтические композиции, содержащие сулбактам и ингибитор бета-лактамазы
WO2017203266A1 (en) Combination therapy for treatment of resistant bacterial infections
ES2929058T3 (es) Composiciones y procedimientos de uso de combinaciones de fármacos antibacterianos
RU2593363C2 (ru) Композиции, включающие антибактериальное средство и тазобактам
TWI725948B (zh) 有效對抗包括抗藥性微生物類之微生物群的組合治療
US8946299B2 (en) Use of calixarenes associated with an antibiotic in the treatment of bacterial infections
CA3053441C (en) COMBINATION OF N-ACETYLCYSTEINE AND COLISTIN INTENDED FOR USE IN BACTERIAL INFECTIONS
CN106794250A (zh) 包含抗菌剂的药物组合物
US20140066365A1 (en) Use of calixarenes associated with an antibiotic in the treatment of bacterial infections
US20200352912A1 (en) Antimicrobial compositions and methods of using the same
WO2015063653A1 (en) Pharmaceutical compositions comprising antibacterial agents
US20150065416A1 (en) Novel drug combination
US10772900B2 (en) Drug target for treating veterinary infections and methods of using same